Please provide your email address to receive an email when new articles are posted on . This analysis focused on adults with moderate to severe COPD without an exacerbation during the ENHANCE trials.
Please provide your email address to receive an email when new articles are posted on . Ensifentrine had favorable efficacy and safety profiles in two phase 3 trials. Verona Pharma is prepared for ...
LONDON and RALEIGH, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results